Omidsci

Human Anti centriole and centrosome antibody IgG ELISA kit

E01A0698-192T 192 tests
EUR 1524
Description: A competitive ELISA for quantitative measurement of Human Anti centriole and centrosome antibody IgG in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Human IgG antibody Laboratories manufactures the omidsci reagents distributed by Genprice. The Omidsci reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Midsci Inc.. Other Omidsci products are available in stock. Specificity: Omidsci Category:

True north Cryobox 15mLBlue

PK10
EUR 212.4

True north Cryobox 50mLNatural

PK10
EUR 210

True north Cryobox 50mLBlue

PK10
EUR 210

True north Cryobox1.5/2mLNatural

PK10
EUR 162

True north Cryobox1.5/2.0mLGreen

PK10
EUR 162

Human true insulin,TI ELISA Kit

96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human true insulin,TI ELISA Kit

96T
EUR 567.6

Chemicals information

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)

78348-1 100 µl
EUR 900
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)

78348-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).

Nucleocapsid Protein (B.1.1.529, Omicron Variant), Avi-His-Tag (SARS-CoV-2)

101319-1 100 µg
EUR 335
Description: Recombinant SARS-CoV-2 Nucleocapsid Protein (also known as N protein), full length encompassing amino acids 1-419 (end). This protein corresponds to SARS-CoV-2 variant B.1.1.529 (Omicron Variant), originally discovered in South Africa, and contains mutations P13L, R203K and G204R. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Nucleocapsid Protein (B.1.1.529, Omicron Variant), Avi-His-Tag (SARS-CoV-2)

101319-2 1 mg
EUR 2730
Description: Recombinant SARS-CoV-2 Nucleocapsid Protein (also known as N protein), full length encompassing amino acids 1-419 (end). This protein corresponds to SARS-CoV-2 variant B.1.1.529 (Omicron Variant), originally discovered in South Africa, and contains mutations P13L, R203K and G204R. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified.

Omipalisib

HY-10297 50mg
EUR 753.6

OMI / HtrA2 Peptide

3051P 0.05 mg
EUR 197.7
Description: (C2) OMI / HtrA2 peptide

HTRA2/Omi antibody

10R-1022 100 ul
EUR 379.2
Description: Mouse monoclonal HtrA2/Omi antibody

HtrA2/Omi Antibody

3497-100 each
EUR 405.6

HtrA2/Omi Antibody

3497R-100 each
EUR 379.2

HtrA2/Omi Antibody

3497R-30T each
EUR 175.2

HtrA2/Omi Antibody

48910-100ul 100ul
EUR 399.6

HtrA2/Omi Antibody

48910-50ul 50ul
EUR 286.8

HtrA2 / Omi Antibody

F54030-0.1ML 0.1 ml
EUR 322.15
Description: Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive. [UniProt]

HtrA2 / Omi Antibody

F54031-0.1ML 0.1 ml
EUR 322.15
Description: Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive. [UniProt]

Omite 1000 ug.mL in HPLC Acetone

LCS-2895 1ML
EUR 189.6

HTRA2 Antibody / Omi

RQ4736 100ul
EUR 356.15
Description: The HTRA2 gene encodes a serine protease. The protein has been localized in the endoplasmic reticulum and interacts with an alternatively spliced form of mitogen-activated protein kinase 14. The protein has also been localized to the mitochondria with release to the cytosol following apoptotic stimulus. The protein is thought to induce apoptosis by binding the apoptosis inhibitory protein baculoviral IAP repeat-containing 4. [RefSeq]

Spike (B.1.1.529, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

78349-1 100 µl
EUR 875
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).Spike Mutations in B.1.1.529 Variant:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F